Jacob Tveiten Bjerrum

Medicin og biovidenskab

1. Colitis 100%
2. Ulcerative Colitis 96%
3. Enterocolitis 72%
4. Infliximab 66%
5. Inflammatory Bowel Diseases 57%
6. Adrenal Cortex Hormones 49%
7. tofacitinib 47%
8. Fecal Microbiota Transplantation 44%
9. tocilizumab 43%
10. Lipidomics 41%
11. Allopurinol 38%
12. Enteritis 37%
13. Azathioprine 34%
14. vedolizumab 31%
15. Microbiota 30%
16. Glucocorticoids 29%
17. Therapeutics 27%
18. Safety 27%
19. Arthritis 26%
20. Wound Healing 26%
21. Immunity 25%
22. Cohort Studies 23%
23. Interleukin-6 23%
24. Denmark 23%
25. Research Personnel 21%
26. Clinical Studies 21%
27. Randomized Controlled Trials 20%
28. Diarrhea 17%
29. Regeneration 17%
30. thiopurine methyltransferase 16%
31. Melanoma 12%
32. Steroids 11%
33. Lipids 10%
34. Biopsy 9%
35. Wounds and Injuries 9%
36. University Hospitals 9%
37. Chronic Disease 9%
38. Biological Therapy 9%
39. Prednisolone 8%
40. Population 8%
41. Sacroiliac Joint 8%
42. Genetic Profile 7%
43. Pediatrics 7%
44. Oral Diagnosis 7%
45. Nivolumab 7%
46. Rheumatologists 7%
47. Ethics Committees 7%
48. Biological Availability 6%
49. Multicenter Studies 6%
50. Dermatologists 6%